FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$15.22
+0.54 (+3.68%)
Open$15.12
Previous Close$14.68
Day High$15.69
Day Low$14.78
52W High$16.93
52W Low$6.47
Volume—
Avg Volume656.6K
Market Cap760.16M
P/E Ratio—
EPS$-2.76
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+38.7% upside
Current
$15.22
$15.22
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 81.26M | 286.9K | 228.58M |
| Net Income | -133,613,648 | -1,099,890,361 | -57,732,834 |
| Profit Margin | -164.4% | -413,039.5% | -25.3% |
| EBITDA | -147,673,299 | -1,322,641,633 | -107,016,126 |
| Free Cash Flow | — | — | -89,291,698 |
| Rev Growth | +200.8% | -87.3% | +10.3% |
| Debt/Equity | — | — | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.99 | -0.08% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.46 | -0.92% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.37 | -1.51% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $799.26 | -0.58% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.45 | -2.07% | 40.0 | 32.33B |